About Voltage-dependent calcium channel gamma-1 subunit
Voltage-dependent calcium channel gamma-1 subunit (CACNG1) is a protein
from Homo sapiens identified by UniProt accession
Q06432, 222 residues long.
MolForge cross-references it against 0 known binders and
31 disease associations.
Target properties
| Protein name | Voltage-dependent calcium channel gamma-1 subunit |
|---|
| UniProt accession | Q06432 |
|---|
| Gene | CACNG1 |
|---|
| Organism | Homo sapiens |
|---|
| Length | 222 residues |
|---|
| Molecular weight | — |
|---|
| EC numbers | — |
|---|
| Target class | UNCLASSIFIED |
|---|
| Subcellular location | — |
|---|
| Keywords | — |
|---|
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
|---|
| Druggability score | — |
|---|
| Pocket score | — |
|---|
| Max clinical phase | — |
|---|
Approved drugs hitting this target (8)
DrugCentral-linked approved drugs that act on this protein.
Disease associations (31)
Diseases linked to this target (Open Targets).
- cardiovascular disease · score 0.46
- generalized anxiety disorder · score 0.39
- Polyuria · score 0.37
- Urinary incontinence · score 0.37
- gastrointestinal disease · score 0.37
- aspartate aminotransferase measurement · score 0.30
- anxiety · score 0.27
- neurodegenerative disease · score 0.26
- breast adenocarcinoma · score 0.25
- adolescent idiopathic scoliosis · score 0.18
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
|---|
| AF-Q06432-F1 | alphafold | PREDICTED | 76.96 | — |
Amino-acid sequence (222 residues)
MSQTKMLKVR VTLFCILAGI VLAMTAVVTD HWAVLSPHME HHNTTCEAAH FGLWRICTKR IPMDDSKTCG PITLPGEKNC SYFRHFNPGE SSEIFEFTTQ KEYSISAAAI AIFSLGFIIL GSLCVLLSLG KKRDYLLRPA SMFYAFAGLC ILVSVEVMRQ SVKRMIDSED TVWIEYYYSW SFACACAAFI LLFLGGLALL LFSLPRMPRN PWESCMDAEP EH
Explore Voltage-dependent calcium channel gamma-1 subunit with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets